Cheryl Nickerson-Nutter

This session will examine how patient advocacy organizations are shaping IPF, PPF, and ILD drug development across the full development lifecycle, with a focus on trial design, regulatory engagement, reimbursement considerations, and sustained patient involvement.

• Explore how patient advocacy groups influence clinical trial design, enrolment strategies, and the selection of meaningful endpoints in IPF, PPF, and ILD studies
• Understand the role of patient organizations in shaping regulatory discussions and supporting access considerations for novel therapies
• Identify practical approaches for pharma to build effective, long-term partnerships with patient groups that extend beyond recruitment into ongoing engagement and advocacy